JAZZ

#3332
Jazz Pharmaceuticals plc - Ordinary Shares
2.3 6 USD
+0.47%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
2.36
2.36
Range Annuel
2.36
243.32
Changement quotidien
+0.47%
Changement Mensuel
-98.83%
Evolution sur 6 mois
-98.64%
Changement Annuel
-98.31%
Clôture Précédente
2.3 5
Open
2.3 6
Low
2.3 6
High
2.3 6
Volume
137
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Nouvelles